PREVALENCE AND PRINCIPLES OF MANAGEMENT OF PATIENTS WITH BARRETT'S ESOPHAGUS


V.V. Tsukanov (1), E.V. Kasparov (1), A.V. Vasyutin (2), E.V. Onuchina (2), Yu.L. Tonkikh (1), N.N. Butorin (3)

(1) FSBI "Scientific Research Institute of Medical Problems of the North", Krasnoyarsk; (2) SBEI FPE "Irkutsk State Medical Academy of Postgraduate Education» of RMPH, Irkutsk; (3) FSBEI HPE "Khakassia State University n.a. N.F. Katanov", Abakan
The article analyzes data on the prevalence and principles of management of patients with Barrett's esophagus. The prevalence of Barrett's esophagus among Caucasians in Siberia varies around 1.5-2.1%. Currently, the leading treatments for Barrett's esophagus include radiofrequency ablation and long-term use of proton pump inhibitors. The chemotherapeutic effect is achieved by the use of aspirin, nonsteroidal anti-inflammatory drugs and ursodeoxycholic acid.

Literature


  1. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–91.
  2. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am. J. Gastroenterol. 2008;103(3):788–97.
  3. Цуканов В.В., Онучина Е.В., Васютин А.В., Буторин Н.Н., Амельчугов О.С. Клинические аспекты гастроэзофагеальной рефлюксной болезни у лиц пожилого возраста: результаты 5-летнего проспективного исследования. Тер. арх. 2014;2:23–6.
  4. Sharma P., Falk G.W., Sampliner R., et al. Management of nondysplastic Barrett’s esophagus: where are we now? Am. J. Gastroenterol. 2009;104(4):805–8.
  5. Di Pietro M., Chan D., Fitzgerald R.C., Wang K.K. Screening for Barrett’s Esophagus. Gastroenterology. 2015;148(5):912–23.
  6. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett’s oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20(Suppl. 5):40–7.
  7. Bennett C., Vakil N., Bergman J., et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143(2):336–46.
  8. Muthusamy V.R., Kim S., Wallace M.B. Advanced Imaging in Barrett’s Esophagus. Gastroenterol. Clin. North. Am. 2015;44(2):439–58.
  9. Ronkainen J., Aro P., Storskrubb T., Johansson S.E., Lind T., Bolling-Sternevald E., Vieth M., Stolte M., Talley N.J., Agrеus L. Prevalence of Barrett’s esophagus in the general population: An endoscopic study. Gastroenterology. 2005;129(6):1825–31.
  10. Lee H.S., Jeon S.W. Barrett esophagus in Asia: same disease with different pattern. Clin. Endosc. 2014;47(1):15–22.
  11. Epub ahead of print
  12. Sharma P., Katzka D.A., Gupta N., et al. Quality Indicators for the Management of Barrett’s Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015;149(6):1599–606.
  13. Halland M., Katzka D., Iyer PG. Recent developments in pathogenesis, diagnosis and therapy of Barrett’s esophagus. World J. Gastroenterol. 2015;21(21):6479–90.
  14. Буторин Н.Н., Бичурина Т.Б., Цуканов В.В. Каспаров Э.В., Куклин Д.В., Тимошенко В.О., Штыгашева О.В., Маады А.С., Васютин А.В. Распространенность и клинические аспекты пищевода Барретта у населения Восточной Сибири. Терапевт. архив. 2013;1:62–5.
  15. Epub ahead of print
  16. Rajendra S., Sharma P. Barrett’s Esophagus. Curr. Treat. Options Gastroenterol. 2014;12(2):169–82.
  17. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.
  18. Shaheen N.J., Overholt B.F., Sampliner R.E., et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–68.
  19. Singh S., Garg S.K., Singh P.P., Iyer P.G., ElSerag H.B. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63(8):1229–37.
  20. Liao L.M., Vaughan T.L., Corley D.A., Cook M.B., Casson A.G., Kamangar F., Abnet C.C., Risch H.A., Giffen C., Freedman N.D., Chow W.H., Sadeghi S., Pandeya N., Whiteman D.C., Murray L.J., Bernstein L., Gammon M.D., Wu A.H. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142(3):442–52.
  21. Corley D.A., Kerlikowske K., Verma R., Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124(1):47–56.
  22. Цуканов В.В., Онучина Е.В., Каспаров Э.В., Васютин А.В., Тонких Ю.Л. Опыт длительной терапии пациентов с пищеводом Барретта. Фарматека. 2015;2:62–5.
  23. Wassenaar E.B., Oelschlager B.K. Effect of medical and surgical treatment of Barrett’s metaplasia. World J. Gastroenterol. 2010;16(30):3773–79.
  24. Gatenby P., Soon Y. Barrett’s oesophagus: Evidence from the current meta-analyses. World J. Gastrointest. Pathophysiol. 2014;5(3):178–87.


About the Autors


V.V. Tsukanov – Doctor of Medical Sciences, Prof. at the FSBIS "Scientific Research Institute of Medical Problems of the North", Head of the Clinical Department of Pathology of the Digestive System in Adults; e-mail: gastro@impn.ru


Similar Articles


Бионика Медиа